Shares of PDS Biotechnology Co. (NASDAQ:PDSB – Get Free Report) have been assigned an average recommendation of “Buy” from the five analysts that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $14.25.
A number of research firms have recently commented on PDSB. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Thursday, October 24th.
Get Our Latest Analysis on PDSB
PDS Biotechnology Stock Performance
PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the company posted ($0.37) earnings per share. Equities analysts anticipate that PDS Biotechnology will post -1.24 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after acquiring an additional 82,135 shares during the period. Blair William & Co. IL grew its holdings in shares of PDS Biotechnology by 204.4% in the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after purchasing an additional 81,743 shares during the last quarter. Tempus Wealth Planning LLC purchased a new position in PDS Biotechnology in the 2nd quarter worth about $55,000. Cubist Systematic Strategies LLC bought a new stake in PDS Biotechnology during the 2nd quarter valued at about $146,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in PDS Biotechnology in the 2nd quarter valued at about $115,000. Institutional investors own 26.84% of the company’s stock.
PDS Biotechnology Company Profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
Recommended Stories
- Five stocks we like better than PDS Biotechnology
- How to Calculate Return on Investment (ROI)
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- MarketBeat Week in Review – 11/4 – 11/8
- Using the MarketBeat Dividend Tax Calculator
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.